Pharmaceutical composition for treating diabetes and indications thereof

A technology for indications and diabetes, which is applied in the field of pharmaceutical compositions for the treatment of diabetes and its indications, can solve the problems of insignificant curative effect of the indications and the like, and achieve the effect of inhibiting blood sugar

Inactive Publication Date: 2013-08-21
苏州博棠再生医学科技有限公司
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the existing drugs can only treat single type I or type I diabetes, and the curative effect on the indications induced by it is not significant

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating diabetes and indications thereof
  • Pharmaceutical composition for treating diabetes and indications thereof
  • Pharmaceutical composition for treating diabetes and indications thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Embodiment 1: the establishment of diabetes model

[0023] In the embodiment of the present invention, the STZ (streptozotocin) method was used to induce type I diabetic rats.

[0024] Preparation of type I diabetes rat model: Take SD rats with a body weight of about 160g, fast for 24 hours, and inject intraperitoneally with a dose of 60 mg STZ / kg body weight (STZ is prepared with 0.05 M citric acid solution (pH4.5) ); 24, 48, and 72 hours later, the blood glucose was measured by docking the tail, and the rats that exceeded 250 mg / dL for 3 consecutive days were determined as diabetic rats; the unsuccessful rats were re-injected with the same amount after 24, 48 hours Rats with blood glucose lower than 250 mg / dL will be excluded, and the rat model thus prepared is a type I diabetes model.

[0025] Preparation of type II diabetes rat model: After feeding the rats with high fat for 4 weeks, a single dose of 100 mg STZ / kg body weight was injected intraperitoneally; Rats w...

experiment example 2

[0026] Experimental Example 2: Preparation and use of drug extraction and drug combination capsules

[0027] Preparation of extracts from turmeric, rhubarb, turmeric, aloe vera, and knotweed: grind appropriate amount of medicinal materials, extract several times with ethanol reflux, filter and combine filtrates, freeze-dry to dryness. The extracts of various medicinal materials are mixed by equal weight to form a medicinal material extraction mixture, and folic acid and coenzyme Q10 are added, and starch is used as a filler to make capsules. The dosage range of each component of each capsule is: the above medicinal material extraction mixture 2.5mg, folic acid 1mg And coenzyme Q10 50mg, processed into capsules with starch as filler. When feeding animals, each capsule is dissolved in 500 ml of feeding water.

Embodiment 3

[0028] Example 3: Inhibition of the combined formulation on α-glucosidase, hexokinase, and aldose reductase

[0029] For the type I diabetes rat model, after being fed with water containing the above drug combination for one month, blood samples were taken from the tail vein, and the activities of α-glucosidase, hexokinase and aldose reductase were measured respectively.

[0030] Referring to the method of Matsui et al., the activity of α-glucosidase was determined with pNP-G as substrate (J. Agri. Food Chem. 2001 (49): 1948-1951), and α-glucosidase (0.1U / ml ) After incubating in a water bath at 37°C for 10 minutes, the substrate pNP-G (2 mM, 0.1ml) was added to initiate the reaction, and after 20 minutes, 1 mL of 0.5 M Na 2 CO 3 Stop the reaction. Finally, measure the light absorption value of p-nitrobenzene released from pNP-G under the action of enzyme at 405nm, and calculate the inhibition efficiency.

[0031] The determination of hexokinase activity is described in re...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a pharmaceutical composition for treating diabetes and indications thereof. The effective component of the medical composition for diabetes and indications consists of a medicinal extract, a coenzyme Q and folic acid. The medicinal extract consists of extracts of radix curcumae, rheum officinale, rhizoma curcumae longae, aloe and Polygonum cuspidatum. The medical composition for treating diabetes and indications can greatly inhibit the activities of three target enzymes: alpha-glucosidase, hexokinase and aldose reductase, and can effectively inhibit rise of blood sugar and blood fat in a diabetic animal model as well as treat indications induced by diabetes such as hyperlipidemia and retinopathy.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to a pharmaceutical composition for treating diabetes and its indications. Background technique [0002] Diabetes is a major and intractable disease that seriously endangers human health. More than one-fifth of people over the age of 50 have diabetes and its induced complications. The drug to treat this kind of disease depends on whether it can effectively control blood sugar concentration. Diabetes is divided into type I and type II according to the difference in insulin resistance. Type I diabetes is caused by insufficient insulin, while type II diabetes is insulin-independent. Therefore, effective ways to treat diabetes are roughly divided into two types: for Type I diabetes is mainly achieved by directly or indirectly increasing the amount or stability of insulin; for type II diabetes, since insulin injection has no significant effect on type II diabetes patients, it is often achieved...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/9066A61P3/10A61P3/06A61P9/10A61K31/122A61K31/519
Inventor 应明刘小青
Owner 苏州博棠再生医学科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap